Both Homology Medicines Inc. (NASDAQ:FIXX) and Xencor Inc. (NASDAQ:XNCR) are Biotechnology companies, competing one another. We will compare their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.
Earnings & Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Homology Medicines Inc. | 3.68M | 227.05 | 57.22M | -2.50 | 0.00 |
Xencor Inc. | 40.60M | 43.12 | 70.41M | -1.35 | 0.00 |
Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Profitability
Table 2 shows the return on assets, return on equity and net margins of the two firms.
Net Margins | Return on Equity | Return on Assets | |
Homology Medicines Inc. | -1,554.89% | 0% | 0% |
Xencor Inc. | -173.42% | -13.3% | -11.9% |
Liquidity
Homology Medicines Inc. has a Current Ratio of 13.2 and a Quick Ratio of 13.2. Competitively, Xencor Inc.’s Current Ratio is 5.9 and has 5.9 Quick Ratio. Homology Medicines Inc.’s better ability to pay short and long-term obligations than Xencor Inc.
Analyst Recommendations
Homology Medicines Inc. and Xencor Inc. Ratings and Recommendations are available on the next table.
Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
Homology Medicines Inc. | 0 | 0 | 1 | 3.00 |
Xencor Inc. | 1 | 0 | 5 | 2.83 |
Homology Medicines Inc. has an average target price of $36, and a 60.79% upside potential. Xencor Inc. on the other hand boasts of a $40.83 average target price and a 31.29% potential upside. The information presented earlier suggests that Homology Medicines Inc. looks more robust than Xencor Inc. as far as analyst opinion.
Institutional and Insider Ownership
Roughly 91.6% of Homology Medicines Inc. shares are held by institutional investors while 85.5% of Xencor Inc. are owned by institutional investors. Homology Medicines Inc.’s share held by insiders are 10.06%. On the other hand, insiders held about 13.5% of Xencor Inc.’s shares.
Performance
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
Homology Medicines Inc. | 6.25% | 41.64% | 30.09% | 80.11% | 0% | 28.4% |
Xencor Inc. | -3.26% | -13.74% | -24.23% | -25.22% | 6.9% | -13.88% |
For the past year Homology Medicines Inc. had bullish trend while Xencor Inc. had bearish trend.
Summary
Homology Medicines Inc. beats on 8 of the 12 factors Xencor Inc.
Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities?gene editing and gene therapy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The companyÂ’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies. Its product candidates also comprise XmAb5574/MOR208, which is in Phase II clinical trials for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia; and XmAb13551 that is in preclinical trials used for the treatment of multiple myeloma. The company has license agreement with Amgen Inc. and MorphoSys Ag to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.